GSK, Kaketsuken Commence Phase III Trials For Cell-Culture Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline and Belgian-based GSK Vaccines and Japan’s Kaketsuken initiate Phase III trials for a cell-culture flu vaccine.